Venus Remedies

336.20
-1.10
(-0.33%)
ann
There are new updates from the company20 hours ago
Viewcross
right
Market Cap
449.40 Cr
EPS
21.31
PE Ratio
16.16
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
427.90
52 Week Low
270.25
PB Ratio
0.91
Debt to Equity
0.09
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Venus Remedies: FDA Grants QIDP Designation for Anti-Microbial Resistance Therapy5 days ago
Venus Remedies' investigational product VRP-034 received Qualified Infectious Disease Product (QIDP) designation from the US FDA for treating bloodstream infections. The stock jumped 14.3% to ₹356.65, an 8-week high, following this announcement.
positive
Venus Remedies Receives QIDP Designation for Novel Antibiotic6 days ago
The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Venus Remedies' VRP-034, a novel formulation of polymyxin B. This designation is given to antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections, potentially expediting the drug's development and review process.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,767.50
#1 4,24,082.46
35.54
#1 49,887.20
12.06
#1 9,648
13.77
55.47
5,914.50
1,57,011.39
75.98
8,184.00
0.89
1,600
#1 64.53
57.94
1,521.30
1,22,862.46
24.73
26,520.70
14.17
4,155
47.38
59.76
3,280.00
1,11,010.10
58.98
10,785.70
11.59
1,656
13.54
55.97
2,538.00
1,04,712.43
52.05
10,615.60
19.57
1,942
-16.38
64.88
1,183.30
98,741.10
#1 18.25
28,905.40
12.36
5,578
1.69
56.24
2,089.90
95,412.49
32.58
20,141.50
#1 19.94
1,936
38.82
53.70
860.00
86,536.12
18.92
19,831.50
13.82
3,831
29.92
44.48
1,190.70
69,156.05
19.57
29,559.20
17.55
3,169
-10.04
57.69
30,915.00
65,692.22
49.34
6,097.20
10.80
1,201
16.01
58.75
Growth Rate
Revenue Growth
8.34 %
Net Income Growth
7.14 %
Cash Flow Change
-10.88 %
ROE
1.21 %
ROCE
11.31 %
EBITDA Margin (Avg.)
-6.60 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
68
92
77
95
75
89
99
84
191
146
128
135
132
205
126
145
145
142
121
159
97
171
146
199
110
178
189
Expenses
57
72
71
98
64
75
86
84
177
115
104
107
113
175
112
137
129
127
109
131
85
150
131
176
97
163
159
EBITDA
11
19
6
-3
11
14
13
0
13
31
24
29
19
30
14
8
16
15
12
28
13
21
14
23
13
16
30
Operating Profit %
15 %
18 %
6 %
-8 %
13 %
14 %
11 %
-2 %
6 %
8 %
15 %
4 %
13 %
13 %
10 %
4 %
10 %
9 %
7 %
16 %
11 %
11 %
8 %
10 %
10 %
3 %
10 %
Depreciation
9
9
9
9
9
9
9
7
9
9
9
9
9
9
9
8
8
9
7
8
8
6
7
6
6
6
5
Interest
8
11
10
0
6
5
4
-2
3
7
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
-6
-0
-12
-12
-4
1
0
-5
2
15
14
18
10
22
5
0
8
6
5
20
5
14
8
18
7
9
25
Tax
0
-1
-1
-0
0
0
1
1
0
2
2
-17
-2
-2
-1
0
1
0
1
9
4
4
1
7
6
6
5
Net Profit
-6
0
-12
-12
-4
0
-1
-5
2
13
12
35
12
23
6
0
7
5
3
11
1
10
7
11
1
4
20
EPS in ₹
-4.70
0.34
-9.50
-9.29
-3.30
0.34
-0.78
-4.38
1.60
10.55
9.44
28.45
8.86
17.32
4.22
0.17
5.16
3.99
2.46
8.27
0.88
7.44
5.13
7.86
0.92
2.63
14.66

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
841
843
765
751
733
644
556
580
601
627
Fixed Assets
444
453
406
389
364
289
262
241
216
219
Current Assets
233
277
259
260
265
294
234
278
323
360
Capital Work in Progress
78
80
66
65
65
25
25
25
26
21
Investments
0
0
0
0
0
0
0
0
20
19
Other Assets
319
310
293
297
304
330
269
314
339
368
Total Liabilities
841
843
765
751
733
644
556
580
601
627
Current Liabilities
163
193
197
230
264
225
97
93
83
79
Non Current Liabilities
222
212
180
159
137
96
58
47
58
60
Total Equity
457
438
389
362
333
323
400
440
460
488
Reserve & Surplus
445
426
376
350
320
311
374
427
447
474
Share Capital
11
11
12
12
12
12
12
13
13
13

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
Net Cash Flow
-1
4
-4
0
-1
-0
27
14
-22
Investing Activities
-67
3
-18
9
-11
-5
57
-17
-58
Operating Activities
68
47
59
31
45
78
132
41
37
Financing Activities
-1
-46
-44
-39
-35
-73
-162
-10
-1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
35.89 %
40.81 %
40.81 %
40.81 %
40.81 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.03 %
1.59 %
1.48 %
1.06 %
1.18 %
1.11 %
1.34 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
54.71 %
51.21 %
51.95 %
52.18 %
51.72 %
49.97 %
50.18 %
50.04 %
49.24 %
48.66 %
48.20 %
47.25 %
46.89 %
46.25 %
45.31 %
45.42 %
46.81 %
Others
9.39 %
7.98 %
7.24 %
7.01 %
7.48 %
8.27 %
7.91 %
8.05 %
8.85 %
9.43 %
8.86 %
9.24 %
9.73 %
10.78 %
11.61 %
11.71 %
10.09 %
No of Share Holders
13,829
13,846
16,617
18,231
19,952
21,189
22,015
22,243
21,719
20,498
19,267
19,560
19,913
19,614
19,557
19,771
19,982

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A20 hours ago
Change In Email Address Of RTA4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Closure of Trading WindowMar 24, 2025
Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To Develop And Commercialize MET-X In IndiaFeb 25, 2025
Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To Develop And Commercialize MET-X In IndiaFeb 25, 2025
Venus Remedies Gets Market Authorization For Anticoagulant Enoxaparin From IndonesiaFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Integrated Filing (Financial)Feb 05, 2025
Intimation Under Regulation 30Feb 04, 2025
Unaudited Financial Results As On 31.12.2024Feb 04, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 04, 2025
Board Meeting Intimation for Board Meeting Scheduled To Be Held On 04Th February 2025Jan 24, 2025
Venus Remedies Limited Successfully Renews EU GMPJan 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Venus Remedies Limited Expands Reach In Eastern European Market With Accreditation Of Good Manufacturing Practice (GMP ) Certification From Ministry Of Health Of MoldovaDec 31, 2024
Venus Remedies Secures Marketing Authorization In PhilippinesDec 06, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 29, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 30, 2024
Financial Results As On 30.09.2024Oct 29, 2024
Board Meeting Outcome for Outcome Of Board Meeting Dated 29.10.24Oct 29, 2024
Board Meeting Intimation for Boar Meeting Is Scheduled For 29Th October 2024.Oct 18, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 05, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 24, 2024
Closure of Trading WindowSep 24, 2024
Announcement under Regulation 30 (LODR)-Change in Management ControlSep 23, 2024
Proceedings Of 35Th Annual General Meeting Held On 23Rd September 2024.Sep 23, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 24, 2024
Reg. 34 (1) Annual Report.Aug 21, 2024
Reg. 34 (1) Annual Report.Aug 21, 2024
Notice Of 35Th Annual General Meeting And Cut-Of-Date/ E-VotingAug 21, 2024
Book Closure NoticeAug 21, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 16, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementAug 13, 2024
Financial Results For The Quarter Ended 30Th June 2024.Aug 13, 2024
Board Meeting Outcome for Outcome Of Board Meeting Dated 13.08.2024Aug 13, 2024
Board Meeting Intimation for Notice Of Board Meeting To Be Held On 13Th August 2024.Aug 01, 2024
Cancellation of Board MeetingJul 17, 2024
Successful Resolution Of Income Tax Case And Refund Of Rs. 21.27 Crores Received By Venus Remedies LimitedJul 12, 2024
Board Meeting Intimation for This Is To Inform You That The Meeting Of Board Of Directors Is Scheduled To Be Held On 20Th July 2024.Jul 10, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateJul 06, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateJun 29, 2024
Closure of Trading WindowJun 26, 2024
Venus Remedies Clinches WHO-Backed PAHO Tender, Takes Its Global Fight Against Cancer To Next LevelJun 20, 2024

Technical Indicators

RSI(14)
Neutral
63.45
ATR(14)
Less Volatile
15.12
STOCH(9,6)
Neutral
63.50
STOCH RSI(14)
Overbought
93.58
MACD(12,26)
Bullish
4.16
ADX(14)
Weak Trend
16.21
UO(9)
Bearish
56.23
ROC(12)
Uptrend And Accelerating
6.66
WillR(14)
Neutral
-27.27